2025

Joint R&D agreement with industry leaders to drive endoscopic product innovation.

2024

Recognized as a national-level "Little Giant" for niche expertise and innovation.

2023

Diversified and platform-integrated single-use endoscope portfolio, global expansion, with EU CE-MDR and U.S. FDA 510(k) clearances for multiple products.

2022

Completed Series C funding, put into operation our new factory, and embraced million-level production capacity.

2021

Completed Series B funding, sent multiple single-use endoscopes for inspection, and planned for automated production lines.

2020

Completed Series A funding, and obtained CE certification on Single-use Video Ureteroscope C12.

2019

Completed system assessment, and obtained certification on image processor.

2018

Raised Pre-A round funding, and put ureterorenoscope into clinical trials.

2017

Finalized products, passed product inspections, and received Angel investment.

2016

Initiated R&D projects, and completed construction of laboratories and workshops with acceptance check passed.

2015

REDPINE was established, headquartered in Guangzhou International Bio Island.